Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19  

作　　者：Yu Lian Zhilin Gao Juanjuan Ti Zhuanzhuan Yu Liangming Ma Jia Wei 

机构地区：[1]Department of Hematology,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Third Hospital of Shanxi Medical University,Taiyuan 030032,China [2]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

出　　处：《Blood Science》2023年第4期269-273,共5页血液科学（英文）

基　　金：from the clinical trial of CAR-T technique in the Treatment of Malignant Hematological Tumors registered on ClinicalTrials.gov(NCT05618041).

摘　　要：1.INTRODUCTION。CD7 is an ideal chimeric antigen receptor(CAR)target for T-cell acute lymphocytic leukemia(T-ALL).Donor-derived CAR-T-cell therapy,as an emerging treatment strategy,shows excellent efficacy in refractory/relapsed(r/r)T-ALL,with over 90%of complete remission(CR),brings new promise to improve prognosis and survival quality,and provides more opportunities for following bridging transplantation.1 However,CD7-CAR-T-cell recipients are always immunocompromised for a number of reasons:depletion of healthy T and NK cells;the need for drugs,which are lymphodepleting,prior to CAR-T-cell therapy;a history of hematological malignancies;multiple-lines chemotherapy;and hematopoietic stem-cell transplantation(HSCT).Meanwhile,patients post donor-derived CAR-T-cell therapy are at high risk of graft-versus-host disease(GVHD)considering infusion of allogeneic cell and increase incidence of infection.

关 键 词：CD7 drugs GVHD 

分 类 号：R563.1[医药卫生—呼吸系统]